HOME >> BIOLOGY >> NEWS
Clinical study reports findings of combination therapy with DOXIL

h as improvement in disease-related symptoms or increased survival.

How DOXIL Works
DOXIL is an advanced form of doxorubicin, a liposomal formulation of doxorubicin, which means that doxorubicin is encapsulated by a fatty bilayer. The liposome is pegylated, which helps protect the drug from the immune system, resulting in the product circulating in the blood for a longer period of time. The longer circulation allows dosing once every four weeks.

Administration
DOXIL is administered intravenously in the doctor's office or clinic. Treatment usually takes from 30 minutes to one hour, though the first treatment may be longer.

  • To manage adverse events such as PPE, stomatitis, or hematologic toxicity, the dose may be delayed or reduced;
  • Pretreatment with or concomitant use of antiemetics should be considered; and
  • Limited clinical experience exists in treating hepatically impaired patients with DOXIL. Based on experience with doxorubicin HCl, it is recommended that DOXIL dosage be reduced if the bilirubin is elevated as follows: Serum bilirubin 1.2 to 3.0 mg/dL give normal dose, >3.0 mg/dL give normal dose.

Efficacy
DOXIL's refractory ovarian cancer indication was based on the results of three Phase II trials involving patients with metastatic ovarian cancer that was resistant to conventional chemotherapy. Most of the patients had been treated with two or more rounds of conventional chemotherapy, but the tumor was still progressing.

In these studies, patients with refractory metastatic ovarian cancer treated with DOXIL had a 13.8% (20/145) (95% CI 8.1% to 19.3%) combined response rate. The median time to response was 18 weeks, median duration of response was 39 weeks, and median time to disease progression was 16 weeks.

Warnings
In clinical trials, the most common side effects reported with DOXIL therapy included reduced red blood cel
'"/>


8-May-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
9. Clinical trial shows timing of chemotherapy improves survival in breast cancer
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):
(Date:6/22/2016)... Cell Applications, Inc. and StemoniX announced ... up to one billion human induced pluripotent stem ... These high-quality, consistent stem cells enable researchers to ... more time doing meaningful, relevant research. This achievement ... process that produces affordable, reliable HiPSC for life ...
(Date:6/22/2016)... --  StockNewsNow.com , The Official MicroCap News Source™, today ... Pourhassan , President & CEO of CytoDyn Inc. (OTCQB: ... and potential commercialization of humanized monoclonal antibodies for the ... company,s website (see here: www.CytoDyn.com ). The video ... 2016, at the LD Micro Invitational in ...
(Date:6/22/2016)... ... , ... New light-based technologies that facilitate a “look inside” the human body ... compact, wearable devices for point-of-care diagnostics as well as powerful new systems that provide ... visionary future directions are detailed in a new open-access article by Antonio Pifferi and ...
(Date:6/22/2016)... and ALBANY, N.Y. , ... (Teewinot) and Albany Molecular Research, Inc. (NASDAQ: ... licensed Teewinot,s technology to produce and sell the ... The CBCA analytical standard is manufactured using Teewinot,s ... expression of cannabinoid biosynthetic genes in microorganisms for ...
Breaking Biology Technology:
Cached News: